• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

4.000 -0.130 (-3.15%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,746,679
Open 4.080
Bid (Size) 4.010 (400)
Ask (Size) 4.100 (40,000)
Prev. Close 4.130
Today's Range 3.970 - 4.135
52wk Range 2.930 - 7.180
Shares Outstanding 38,886,465
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
October 15, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
October 14, 2026
From Eton Pharmaceuticals; Aquestive Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 44.3% below 52-week high
4.000
2.9352W Low 7.1852W High
1 Week 4.4% below 1-week high
3.651W Low 4.181W High

Aquestive Therapeutics, Inc. - Common Stock (AQST) traded between $2.93 and $7.18 over the past 52 weeks and last traded at $4.00, 44.3% below its 52-week high. Over the past week it ranged between $3.65 and $4.18.

Past 12 Months
+4.4%
-17.0%
+7.2%
-2.4%
-38.0%
-41.5%
1W +$0.17
1M -$0.82
3M +$0.27
6M -$0.10
YTD -$2.45
1Y -$2.84

AQST was -41.5% over the past year, -2.4% over six months, -38.0% year to date, +4.4% in the last week.

12 Months vs Market
AQST
-41.5%
DIA
+10.4%
SPY
+12.2%
QQQ
+14.1%
IWM
+10.6%

Over the past 12 months AQST returned -41.5% versus DIA (Dow) +10.4%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +14.1% and IWM (Russell 2000) +10.6%.

Volume & Liquidity 0.63× 3-mo avg
Today 1,746,679 3-mo avg 2.8M
1W
2.2M
1M
2.2M
3M
2.8M
6M
2.3M
YTD
3.0M
1Y
2.9M

AQST most recently traded 1,746,679 shares against a 3-month average daily volume of 2.8M.

More News

Read More
News headline image
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
September 29, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
September 17, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
September 01, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive (AQST) Q2 2026 Earnings Call Transcript ↗
August 18, 2026
Via The Motley Fool
Topics Earnings
News headline image
Aquestive Therapeutics Q2 Earnings Call Highlights ↗
August 12, 2026
Via MarketBeat
Topics Earnings
News headline image
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
August 10, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
July 29, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
July 07, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
AQST Q1 2026 Earnings Call Transcript ↗
May 14, 2026
Via The Motley Fool
Topics Earnings
News headline image
Aquestive Therapeutics Q1 Earnings Call Highlights ↗
May 14, 2026
Via MarketBeat
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
May 13, 2026
Via Chartmill
News headline image
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
May 12, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
May 06, 2026
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
May 04, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
May 02, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
AQUESTIVE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
May 01, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
April 29, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
April 28, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
AQUESTIVE DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
April 28, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
April 21, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
April 21, 2026
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Aquestive Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aquestive Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aquestive Therapeutics, Inc. - Common Stock trade on?
Aquestive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aquestive Therapeutics, Inc. - Common Stock?
The ticker symbol for Aquestive Therapeutics, Inc. - Common Stock is AQST on the Nasdaq Stock Market
What is the current price of Aquestive Therapeutics, Inc. - Common Stock?
The current price of Aquestive Therapeutics, Inc. - Common Stock is 4.000
When was Aquestive Therapeutics, Inc. - Common Stock last traded?
The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 10/23/26 04:00 PM ET
What is the market capitalization of Aquestive Therapeutics, Inc. - Common Stock?
The market capitalization of Aquestive Therapeutics, Inc. - Common Stock is 155.55M
How many shares of Aquestive Therapeutics, Inc. - Common Stock are outstanding?
Aquestive Therapeutics, Inc. - Common Stock has 156M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap